Last reviewed · How we verify
Steroid Drug (prednisolone)
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica), Allergic reactions and asthma, Adrenal insufficiency.
At a glance
| Generic name | Steroid Drug (prednisolone) |
|---|---|
| Sponsor | Lumbini Medical College |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug has broad anti-inflammatory and immunosuppressive effects across multiple cell types and tissues.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica)
- Allergic reactions and asthma
- Adrenal insufficiency
- Certain hematologic malignancies and lymphomas
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia / glucose intolerance
- Hypertension
- Osteoporosis / bone loss
- Immunosuppression / increased infection risk
- Insomnia / mood changes
- Cushingoid features (with chronic use)
- Gastrointestinal upset
- Hypokalemia
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Steroid Drug (prednisolone) CI brief — competitive landscape report
- Steroid Drug (prednisolone) updates RSS · CI watch RSS
- Lumbini Medical College portfolio CI